How Jeanmarie Guenot Looks To Cleanly Kill Cancer

Dr. Jeanmarie Guenot, Ph.D., is a leader in the cancer research community. She has dedicated her career to irradicating cancer through the use of innovative drug therapies. She has years of experience as both a researcher as well as a business leader. She earned her Ph.D. at the University of California, San Francisco and her MBA at the Unversity of Pennsylvania – The Wharton School.

Dr. Jeanmarie Guenot started her career as a Principal Scientist at Hoffman-La Roche where she performed research and development into cancer drug therapies. She became an executive level leader in 2003 at PDL Biopharma where she was the Vice President of Corporate and Business Development. Since then she has also founded two companies; Guenot, LLC and SKS Ocular, LLC and served both companies as their Managing Partner. She was also the President and Chief Executive Officer of Amphivena Therapeutics, Inc., a San Francisco-based company that is engaged in developing drugs to fight cancer. At Amphivena Therapeutics, Dr. Jeanmarie Guenot was focused on developing bifunctional antibody therapies which are designed to treat different forms of blood-borne cancer.

Read more: Maverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T-Cell Engagement Therapies

Dr. Guenot is now the Chief Executive Officer of another San Francisco biotechnology company, Maverick Therapeutics, Inc. Dr. Guenot has explained that a lot of drugs that treat cancer also destroy so much nearby tissue that in the end, the patient has gained little. She ends to change this state of affairs with a drug under development at Maverick Therapeutics on Crunchbase. The way her cancer drug will do this is by using the patient’s own T cells to fight cancer. T cells are white blood cells that are a necessary part of the body’s reaction to foreign invaders and make up a person’s immune system. Dr. Guenot said that her company will have a drug out within the next five years which will be able to cleanly kill cancer and not destroy other, healthy nearby tissue.

Under Dr. Guenot’s leadership, Maverick Therapeutics has raised $125 million in funding from Takeda Pharmaceutical Co. Ltd, headquartered in Japan, and the venture capitalist firm MPM Capital.

Learn more about Jeanmarie Guenot: http://www.guenotllc.com/Biography.html

Sawyer Howitt – Son of Meriwether Group Founder

The Meriwether Group offers funding, acceleration, and exit strategy support for startups and businesses looking to grow. It funds companies with equity or debt. A team of 12 talented people brings its collective experience and business understanding to help entrepreneurs realize business success. The company sees entrepreneurs as modern day heroes. These are the people who make a major impact on society by the products and services they create.

David Howitt is the founder of the Meriwether Group. He and his wife Heather have two children: Sawyer Howitt and Hailey. These two are fortunate to have a talented father who can help pave the way for their success in life. Visit This Page.